Use of dry powder inhalers in acute exacerbations of asthma and COPD

Abstract

To investigate whether dry powder inhalers (DPIs) function in a constrained situation, a literature analysis was performed to evaluate the use of DPIs compared with established therapies in the treatment of acute asthma and COPD, irrespective of rapid-acting β₂-agonist used. The external databases Medline, Embase, Biosis and Current Contents and AstraZeneca's internal literature database Planet were searched up to April 2008. Only publications or congress abstracts describing clinical trials in patients treated at EDs or hospitals were considered, and then only those in which exacerbation severity (measured as FEV₁) were included. Fifteen clinical studies met these criteria; twelve in acute asthma and three in acute COPD. For acute asthma, eight studies were double-blind, randomised studies (six in adults and two in children), two were open-label studies (one in adults and one in children), and two were investigational (methacholine challenge) studies. For the acute COPD studies, one was double-blind and randomised, one was single-blind and randomised, and one was open-label. This review found that administration of fast-acting bronchodilators via DPIs, the majority of which were Turbuhaler, is effective during an asthma or COPD worsening. Our literature review finds that DPIs function in patients with acute asthma or COPD equally well as established therapies with other inhaler devices. Patients can therefore rely upon DPIs in the same way that they rely upon other inhaler devices.

Keywords

Dry powder inhaler DPI Turbuhaler exacerbation worsening hospitalization asthma COPD

References

Balanag, V.M. , Yunus, F. , Yang, P.-C. and Jorup, C. (2006) Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther 19: 139-147.

Boonsawat, W. , Charoenratanakul, S. , Pothirat, C. , Sawanyawisuth, K. , Seearamroongruang, T. , Bengtsson, T. et al. (2003) Formoterol (OXIS®) Turbuhaler® as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med 97: 1067-1074.

Borgström, L. (2001) On the use of dry powder inhalers in situations perceived as constrained. J Aerosol Med 14: 281-287.

Broeders, M.E.A.C. , Molema, J. , Hop, W.C.J. , Vermue, N.A. and Folgering, H.T.M. (2004) The course of inhalation profiles during an exacerbation of obstructive lung disease. Respir Med 98: 1173-1179.

Cazzola, M. , D'Amato, M. , Califano, C. , Di Perna, F. , Calderaro, F. , Matera, M.G. et al. (2002) Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin Ther 24: 595-604.

Cazzola, M. , Salzillo, A. , De Giglio, C. , Noschese, P. and D'Amato, G. (2003) Formoterol/budesonide (FBC) in the treatment of acute exacerbation of COPD. Eur Respir J 22(Suppl. 45): 288s, P1859.

Chuchalin, A. , Makarova, I. and Bergqvist, P. (2003) As-needed formoterol has an improved safety profile compared with as-needed terbutaline in mild intermittent asthma. Eur Respir J 22(Suppl. 45): 235s, P1571.

Cordova, E.R. and Accinelli, R.A. (2004) Formoterol-Turbuhaler vs albuterol-MDI in adults with acute asthma in the emergency room. Am J Respir Crit Care Med 2004; 169(Suppl.): A313.

Drblik, S. , Lapierre, G. , Thivierge, R. , Turgeon, J. , Gaudreault, P. , Cummins-McManus, B. et al. (2003) Comparative efficacy of terbutaline sulphate delivered by Turbuhaler dry powder inhaler or pressurised metered dose inhaler with Nebuhaler spacer in children during an acute asthmatic episode. Arch Dis Child 88: 319-323.

10.

Freedman, B.J. (1972) Trial of a terbutaline aerosol in the treatment of asthma and a comparison of its effects with those of a salbutamol aerosol . Br J Dis Chest 66: 222-229.

11.

Global Initiative for Asthma (2007) Global strategy for asthma management and prevention. Updated 2007 . Available at: www.ginasthma.com, accessed September 2008.

12.

Global Initiative for Chronic Obstructive Lung Disease (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2007. Available at: www.goldcopd.com, accessed September 2008.

13.

Green, R. , Clay, M. and Woodcock, A. (1996) The Accuhaler/Diskus inhaler for delivering salbutamol during bronchoconstriction. Am J Respir Crit Care Med 153: A61.

14.

Grunfeld, A. , Shragge, D.L. , Dent, J.M. , Soliman, S. , Svensson, K.J. and Fitzgerald, J.M. (1996) Greater bronchodilation from Bricanyl Turbuhaler over Bricanyl pressurized metered dose inhaler in patients with acute asthma in the emergency department. Am J Respir Crit Care Med 153: A61.

15.

Jonkers, R.E. , Bantje, T.A. and Aalbers, R. (2006) Onset of relief of dyspnoea with budesonide/ formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study. Respir Res 7: 141.

16.

Juniper, E.F. , Svensson, K. , Mork, A-C. and Stahl, E. (2004) Measuring health-related quality of life in adults during an acute asthma exacerbation. Chest 125: 93-97.

17.

Lindmark, B. (2008) Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/ fluticasone reflect differences in their therapeutic usefulness in asthma. Ther Adv Respir Dis 2: 279-299.

18.

McNeill, R.S. , Malcolm, G.D. and Rhind Brown, W. (1959) A comparison of expiratory and inspiratory flow rates in health and in chronic pulmonary disease. Thorax 14: 225-231.

19.

Nana, A. , Youngchaiyud, P. , Charoenratanakul, S. , Boe, J. , Lofdahl, C.G. , Selroos, O. et al. (1998) High-dose inhaled budesonide may substitute for oral therapy after an acute asthma attack. J Asthma 35: 647-655.

20.

Pauwels, R.A. , Sears, M.R. , Campbell, M. , Villasante, C. , Huang, S. , Lindh, A. et al. (2003) Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 22: 787-794.

21.

Phanareth, K. and Laursen, L.C. (1999) Bricanyl Turbuhaler versus nebuliser in the treatment of patients with acute severe airways obstruction. Eur Respir J 14(Suppl. 30): 61s.

22.

Richter, K. (2004) Successful use of DPI systems in asthmatic patients - key parameters. Respir Med 98(Suppl. B): S22-S27.

23.

Rubinfeld, A.R. , Scicchitano, R. , Hunt, A. , Thompson, P.J. , Van Nooten, A. and Selroos, O. (2006) Formoterol Turbuhaler® as reliever medication in patients with acute asthma. Eur Respir J 27: 735-741.

24.

Seberova, E. and Andersson, A. (2000) Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 94: 607-611.

25.

Sole, D. , Rizzo, M.C.F.V. , Pimentel, A.F. , Sano, F. , Barreto, B.A. , Wandalsen, N.F. et al. (1995) Effect of inhaled terbutaline sulphate (dry powder, Turbuhaler(TM) and nebulizer solution) in children with acute asthma . Jornal de Pediatria 71: 82-87.

26.

Springer, C. , Stahl, E. , Schachter, J. and Avital, A. (1996) Terbutaline given via Turbuhaler and in nebulised form in children with acute asthma. Eur J Clin Res 8: 163-169.

27.

van den Broek, K.M. , Wielders, P.L.M.L. , Creemers, J.P.H.M. and Smeenk, F.W.J.M. (2008) Efficacy of formoterol Turbuhaler in the emergency treatment of patients with obstructive airway diseases. Respir Med 102: 579-585.